« All that's Lilly that's Fit to Print | Main | Big Biotech to go the Way of the DoDo »

11/09/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0133f5b65eb8970b

Listed below are links to weblogs that reference More on Prostate Cancer News:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

treat prostate cancer naturally

That's sad news for those who are using the same treatment mentioned above. Thanks for the information though.

Account Deleted

It's interesting, I listened to the same webcast live early this morning.

While the company did indeed say that they were talking to potential partners, including some in Top 10 pharma, that is never any guarantee that a deal will be made in the near term.

There is no guarantee that promising phase II results will translate to positive phase III data either, especially in oncology.

What Bavarian Nordic do potentially offer over Dendreon's Provenge in the long run is a more streamlined mass market manufacturing process and a global phase III program. They suggested this morning that the new trial potentially starting in 2011 (assuming SPA agreement from the FDA is forthcoming) will be 60:40 for ROW:US, thus broadening access and appeal for a global company interested in active partnering.

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada